# Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT03537807** · — · NO_LONGER_AVAILABLE · sponsor: **Biohaven Pharmaceuticals, Inc.**

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS
- Lou Gehrig Disease
- Lou Gehrig's Disease
- Lou-Gehrigs Disease
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Riluzole

## Key facts

- **NCT ID:** NCT03537807
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537807, "Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03537807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*